1e9ebe7725a56d302a8eab8f7a96fb3b0f0e3972
ETS1.md
| ... | ... | @@ -1,10 +1,7 @@ |
| 1 | 1 | # ETS1 |
| 2 | 2 | |
| 3 | -<<Warn("The variants reported in this gene in BL failed QC")>> |
|
| 4 | - |
|
| 5 | -**[See below ](#representative-mutations) or [the study page ](papers/paneaWholeGenomeLandscape2019.md#tier-2) for more information** |
|
| 6 | - |
|
| 7 | 3 | ## Overview |
| 4 | + |
|
| 8 | 5 | ETS1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. |
| 9 | 6 | This gene has some recurrent sites of mutations (hot spots). |
| 10 | 7 | The mutation pattern in DLBCL implies the preferential accumulation of *inactivating mutations*. |
| ... | ... | @@ -24,7 +21,7 @@ timeline |
| 24 | 21 | |:------:|:----:|--------------------------------------| |
| 25 | 22 | ||1|high-confidence PMBL/cHL/GZL gene| |
| 26 | 23 | | |1-a | aSHM target and high-confidence DLBCL gene | |
| 27 | -| |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous | |
|
| 24 | +| |2-F | Failed QC| |
|
| 28 | 25 | |
| 29 | 26 | ## Mutation incidence in large patient cohorts (GAMBL reanalysis) |
| 30 | 27 |